These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 6648155)

  • 1. Unbiased assessment of treatment effects on disease recurrence and survival in clinical trials.
    Haybittle J
    Stat Med; 1983; 2(3):415-6. PubMed ID: 6648155
    [No Abstract]   [Full Text] [Related]  

  • 2. [Evaluation of medical practices].
    Battista RN
    Union Med Can; 1980 Oct; 109(10):1462-7. PubMed ID: 6781111
    [No Abstract]   [Full Text] [Related]  

  • 3. [Alternative clinical therapeutic evaluation].
    Uberla KK
    Verh Dtsch Ges Inn Med; 1980; 86():1291-6. PubMed ID: 7223006
    [No Abstract]   [Full Text] [Related]  

  • 4. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Demonstration of a similarity of effect among several therapies: technics and value in medical decision-making].
    Lacaine F; Rodary C; Flamant R
    Gastroenterol Clin Biol; 1981; 5(6-7):599-603. PubMed ID: 7250612
    [No Abstract]   [Full Text] [Related]  

  • 6. Public / private partnership: developing an oral treatment for visceral leishmaniasis.
    Mattock N
    TDR News; 1999 Oct; (60):1-2. PubMed ID: 12295471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutics for patients with non-muscle-invasive bladder cancer.
    Svatek RS; Kamat AM; Dinney CP
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):807-13. PubMed ID: 19496717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to read clinical journals: V: To distinguish useful from useless or even harmful therapy.
    Can Med Assoc J; 1981 May; 124(9):1156-62. PubMed ID: 7016293
    [No Abstract]   [Full Text] [Related]  

  • 9. Using auxiliary variables for improved estimates of survival time.
    Lagakos SW
    Biometrics; 1977 Jun; 33(2):399-404. PubMed ID: 884198
    [No Abstract]   [Full Text] [Related]  

  • 10. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient heterogeneity in clinical trials.
    Simon R
    Cancer Treat Rep; 1980; 64(2-3):405-10. PubMed ID: 7407777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The measurement parameters and statistical analysis of therapeutic study].
    Zhou ZT; Yao H
    Shanghai Kou Qiang Yi Xue; 2004 Aug; 13(4):241-5. PubMed ID: 15349653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of survival curves: Logrank test (author's transl)].
    Rodary C; Laplanche A; Com Nougue C; Flamant R
    Bull Cancer; 1981; 68(2):201-4. PubMed ID: 7016226
    [No Abstract]   [Full Text] [Related]  

  • 14. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group.
    J Natl Cancer Inst; 1997 Apr; 89(7):497-505. PubMed ID: 9086006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential clinical trials for normal variates using interval composite hypotheses.
    Lachin JM
    Biometrics; 1981 Mar; 37(1):87-101. PubMed ID: 7248445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
    Tang SC
    Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A statistical note: selection of an endpoint.
    Lee JY
    Am J Clin Oncol; 1982 Jun; 5(3):261-5. PubMed ID: 7081145
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Conservative experimental groups in clinical comparative trials. Tables providing the minimum number of patients].
    Lehmann EH; Sandvik H
    Tidsskr Nor Laegeforen; 1996 Aug; 116(18):2183-5. PubMed ID: 8801663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Multicenter clinical trials: a pressing need for the development of new therapeutics].
    Boissel JP; Jaillon P; Delahaye JP; Bounhoure JP
    Arch Mal Coeur Vaiss; 1986 Sep; 79(10):1393-4. PubMed ID: 3099673
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.